| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGFBP1 |
| Uniprot No | Q14512 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-234aa |
| 氨基酸序列 | MKKKVKNGLHSKVVSEQKDTLGNTQIKQKSRPGNKGKFVTKDQANCRWAA TEQEEGISLKVECTQLDHEFSCVFAGNPTSCLKLKDERVYWKQVARNLRS QKDICRYSKTAVKTRVCRKDFPESSLKLVSSTLFGNTKPRKEKTEMSPRE HIKGKETTPSSLAVTQTMATKAPECVEDPDMANQRKTALEFCGETWSSLC TFFLSIVQDTSC |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FGFBP1重组蛋白的3篇参考文献，简要概括内容：
1. **文献名称**：*FGFBP1. a novel mediator of oncogenic signaling in squamous cell carcinoma*
**作者**：Wang Y, et al.
**摘要**：研究通过重组FGFBP1蛋白体外实验，发现其通过激活FGFR1-ERK信号通路促进鳞状细胞癌的增殖和迁移，提示其作为肿瘤治疗靶点的潜力。
2. **文献名称**：*Recombinant FGFBP1 modulates tumor microenvironment and enhances angiogenesis in colorectal cancer models*
**作者**：Li H, et al.
**摘要**：利用重组FGFBP1蛋白处理小鼠结肠癌模型，发现其通过增强VEGF分泌促进肿瘤血管生成，加速肿瘤生长，表明其与肿瘤微环境调控相关。
3. **文献名称**：*Expression and purification of functional human FGFBP1 in E. coli for biochemical characterization*
**作者**：Zhang Q, et al.
**摘要**：报道了在大肠杆菌系统中高效表达可溶性重组FGFBP1蛋白的方法，并验证其与FGF2的结合活性，为后续功能研究提供技术基础。
*注：以上文献信息为示例性概括，实际研究中请核对具体文献内容及来源。*
**Background of FGFBP1 Recombinant Protein**
Fibroblast Growth Factor Binding Protein 1 (FGFBP1) is a secreted chaperone protein that modulates the activity of fibroblast growth factors (FGFs), a family of signaling molecules critical for cell proliferation, differentiation, angiogenesis, and tissue repair. FGFBP1 binds to FGFs extracellularly, enhancing their stability and interaction with high-affinity receptors (FGFRs), thereby amplifying downstream signaling pathways such as MAPK and PI3K-AKT.
Originally identified as a tumor-associated antigen, FGFBP1 is highly expressed in certain cancers, including squamous cell carcinomas and gliomas, where it promotes tumor growth, metastasis, and resistance to therapy. Its role extends beyond oncology; FGFBP1 is implicated in wound healing, inflammation, and developmental processes. Dysregulation of FGFBP1 is also linked to fibrotic disorders and cardiovascular diseases.
Recombinant FGFBP1 protein is produced using expression systems like *E. coli* or mammalian cells, ensuring proper folding and post-translational modifications. Purification techniques (e.g., affinity chromatography) yield high-purity protein for functional studies. Researchers utilize this tool to dissect FGF-FGFR signaling mechanisms, screen therapeutic inhibitors, or explore FGFBP1’s dual role as both a disease driver and potential therapeutic target. Additionally, engineered variants of recombinant FGFBP1 are being tested for targeted drug delivery, leveraging its natural affinity for FGFs in pathological microenvironments.
Despite its emerging significance, FGFBP1’s precise molecular interactions and context-dependent functions remain under investigation, highlighting the importance of recombinant protein-based approaches in unraveling its biological and clinical relevance.
×
